PMN:TSX; PMN:NCM

ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded proteins implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts.
PMN:TSX PMN:NCM

Expert Comments:

headshot of Douglas Loe

Douglas Loe, Leede Jones Gable

(9/28/22)
"We remain positive about the role that ProMIS Neurosciences Inc.'s PMN-310 could play in mitigating Alzheimer's disease progression through its documented amyloid-oligomer-specific binding, and we are thus encouraged that a related monoclonal antibody that also targets an amyloid oligomer form has not solidly demonstrated clinical efficacy on mitigating cognitive impairment in a large and well-controlled Phase 3 study. We believe that Clarity AD/lecanemeb data thus provide supporting evidence for our PMN-310-based investment thesis for ProMIS and for the role of oligomers/protofibrils in AD pathophysiology."

read more >

Douglas Loe, Leede Jones Gable

(8/5/22)
"ProMIS Neurosciences Inc. and its scientific collaborators presented new preclinical/biochemical data that further characterized the beta amyloid-binding activity of the firm's novel monoclonal antibody (mAb) drug PMN310, showing in a series of experiments that the mAb has a unique binding profile when compared to other amyloid-targeted mAbs. . .new PMN310 amyloid binding data is consistent with our prior analysis showing how selectively PMN310 binds to neurotoxic beta amyloid oligomers and not to monomers or higher order plaques."

Steve Silver, Argus Research

(7/6/22)
"ProMIS Neurosciences Inc. has designated PMN267, focused on TDP-43, as its lead product candidate for treatment of amyotrophic lateral sclerosis (ALS). To date, an intrabody version of PMN267, delivered inside cells via a gene therapy vector, has shown significant reductions in the amount of TDP-43 aggregates in human motor neurons derived from ALS patients, and an injectable antibody treatment has produced promising trends for protection against disability."

headshot of Douglas Loe

Douglas Loe, Leede Jones Gable

(7/6/22)
"Earlier this week, ProMIS Neurosciences Inc. competitor, Eisai, received priority review status from the U.S. Food and Drug Administration (FDA) for a Phase 3-stage beta amyloid-targeted monoclonal antibody called lecanemab. . .protofibril-targeted lecanemab exhibits binding selectivity to intermediate oligomeric forms of beta amyloid, and so favorable FDA review could reflect positively on PMN310's downstream clinical/regulatory prospects."

read more >

Steve Silver, Argus Research

(6/27/22)
"ProMIS Neurosciences Inc.'s PMN310 program is currently undergoing investigational new drug enabling activities and is expected to begin a Phase 1b clinical study in Alzheimer's disease patients in early 2023. . .we view PMN310 as potentially representing a best-in-class opportunity."

headshot of Douglas Loe

Douglas Loe, Leede Jones Gable

(5/11/22)
"We are initiating coverage on Massachusetts-based, central nervous system-focused, antibody-based drug developer ProMIS Neurosciences Inc. with a Speculative Buy rating. . .the company's core competency lies in its expertise in generating monoclonal antibodies that target conformational epitopes that are expressed either predominantly or exclusively on misfolded or aggregated proteins that in being misfolded/aggregated contribute to disease."

read more >

More Expert Comments

Experts Following This Company

headshot of Douglas Loe
Douglas Loe, Managing Director & Analyst, Healthcare and Biotechnology – Leede Jones Gable
Steve Silver, Outside IR – KCSA Strategic Communications
John Vandermosten, CFA – Zacks Small-Cap Research

Company News 

9/13/2022 – ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

8/15/2022 – ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

8/2/2022 – ProMIS Neurosciences Presents at 2022 Alzheimer's Association International Conference

7/27/2022 – ProMIS Neurosciences to Present at 2022 Alzheimer's Association International Conference

7/8/2022 – ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol "PMN"

The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Alzheimer’s antibody therapy potentially “Best” of next generation
 
Highly selective antibody technology targets only misfolded (toxic) proteins
 
Proprietary discovery platform supports broad, rapidly expanding portfolio
catalyst Calendar
Q2
2022
Start IND enabling studies for Parkinson’s and ALS lead candidates: H2 2022
Q4
2022
PMN310 for Alzheimer’s: IND preparation complete Q4’2022
Q1
2023
First clinical trial Q12023